Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
DZI Cherney, BA Perkins, N Soleymanlou… - Kidney …, 2014 - kidney-international.org
To the Editor: Recently, Musetti et al. commented on the potential renal effects of sodium
glucose co-transport-2 inhibition (SGLT2-i), as reviewed by Gilbert. 1, 2 They specifically
elaborated on Gilbert's hypothesis that SGLT2-i may be reminiscent of renin–angiotensin
system (RAS) blockade, indicating that such an intervention may also downregulate the
RAS, thereby increasing the risk of hyperkalemia and hemodynamic kidney injury. We agree
that SGLT2-i exerts a RAS inhibition-like effect on renal function; however, this therapy is not …
glucose co-transport-2 inhibition (SGLT2-i), as reviewed by Gilbert. 1, 2 They specifically
elaborated on Gilbert's hypothesis that SGLT2-i may be reminiscent of renin–angiotensin
system (RAS) blockade, indicating that such an intervention may also downregulate the
RAS, thereby increasing the risk of hyperkalemia and hemodynamic kidney injury. We agree
that SGLT2-i exerts a RAS inhibition-like effect on renal function; however, this therapy is not …